## 1 Introduction  
The global health system has worked hard to protect and promote human health. However, the world continues to face newly emerging infectious disease threats. The lack of effective antimicrobial drugs for the prevention and treatment of infections complicates many medical procedures, including cancer and diabetes therapy and organ transplantation. The biggest problem in the fight against infectious diseases is the rapid formation of resistance to existing drugs [1, 2]. Many infections remain critical due to the increasing antibiotic resistance of pathogens belonging to different groups of microorganisms. One of the most important infectious agents is _Staphylococcus aureus_. This Gram-positive bacterium is a widespread pathogen that can colonize many biotopes in the human and animal body, causing various diseases. _S. aureus_ shows increasing antibiotic resistance to current antibiotics, especially \(\beta\)-lactams [3, 4]. Insensitivity to many antibiotics is also widespread among a special group of microorganisms--mycobacteria. These bacteria have a special cell wall structure, which has low permeability to various substances, including antibacterial agents. Mycobacteria cause a number of difficult-to-treat diseases, primarily tuberculosis, which has long been one of the leading causes of death [5]. It should also be noted that fungal infections, including candidiasis, are quite widespread at present. _Candida albicans_ is the most implicated fungal species, and grows as an opportunistic pathogen in the human host. It is associated with many life-threatening infections, especially in immunocompromised persons, and can cause sepsis [6]. An important feature of microorganisms is their ability to form biofilms, which is another challenge associated with the treatment of infectious diseases. Biofilms are multicellular microbial assemblages surrounded by a matrix composed of polysaccharides containing extracellular DNA, proteins, and lipids. Biofilms allow bacteria to grow on medical devices, leading to chronic infections. Cells in the biofilm have reduced sensitivity to antibiotics and effectors of the host immune system. Antibiotics that show antibiotifm activity, especially against _S. aureus_, are limited. This is a very important task--the search for agents that can effectively destroy microorganisms resistant to traditional antibiotics, as well as cells in biofilms. Benzimidazole is an important pharmacophore fragment in the drug discovery process since it exhibits various therapeutic properties [7; 8]. For example, bendamustine (Treanda) is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (Figure 1) [9]. Bendazol (Dibazol) demonstrates immunostaining as well as vasodilating and antispasmodic effects [10]. Omeprazole is a drug that inhibits gastric acid secretion and is used in the treatment of gastric ulcers [11]. Fuberidazole and Benomyl (Benlate) are the active ingredients of fungicides [12; 13]. Tecanetzolice (Norastemizole) shows antiinflammatory activity [14]. It is worth noting that indole derivatives exhibit a wide range of biological activities [15]: antiproliferative, antioxidant [16], antiviral [17], antibacterial, and antifungal [18]. The combination of a benzimidazole moiety with an additional azaheterocycle in a single molecule may promise a synergistic enhancement of therapeutic effect. Derivatives of benzimidazole exhibit diverse activities by interacting with numerous biomolecular targets. It is known that 2,5,6-trisubstituted benzimidazoles demonstrate antitubercular activity by targeting filamentous temperature-sensitive protein \(Z\) (FtsZ) [19]. This protein plays a crucial role in bacterial cell division, making it a promising target for the development of antibacterial agents against various bacterial pathogens. Moreover, compounds containing a benzimidazole fragment have been identified as inhibitors of essential pyruvate kinase enzymes, exhibiting antistaphylococcal activity [20; 21].